Novo has contributed to a series A round for Genoa Pharmaceuticals, which is aiming to get its IPF treatment into clinical trials this year.
Genoa Pharmaceuticals, a US-based developer of treatments for pulmonary diseases, closed a $62m series A round yesterday that included pharmaceutical firm Novo.
F-Prime Capital Partners, an investment subsidiary of financial services group Fidelity, co-led the round with banking and asset management group Edmond de Rothschild Investment Partners, investing alongside RiverVest Venture Partners and TPG Biotech.
Genoa Pharmaceuticals is working on therapeutics for pulmonary diseases including idiopathic pulmonary fibrosis (IPF). Its lead program, centred on an inhaled treatment dubbed Aerodone, is…
